Good morning :)
Place Order
Add to Watchlist

Nectar Lifesciences Ltd

NECLIFE Share Price

16.470.00% (+0.00)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹369 cr, stock is ranked 2,051

Stock is 4.57x as volatile as Nifty

NECLIFE Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

Avg

Can be considered moderately valued vs the market

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

With a market cap of ₹369 cr, stock is ranked 2,051

Stock is 4.57x as volatile as Nifty

NECLIFE Performance & Key Metrics

NECLIFE Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-3.250.35
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
36.776.430.79%

NECLIFE Analyst Ratings & Forecast

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

NECLIFE Company Profile

Nectar Lifesciences Limited is a pharmaceutical company. The Company's operations include manufacturing and marketing of oral and sterile cephalosporin's, phytochemicals and allied products.

NECLIFE Similar Stocks (Peers)

Compare with peers Compare with peers 

NECLIFE Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
36.65
36.65
1Y Return
5.30%
5.30%
Buy Reco %
87.50
87.50
PE Ratio
22.85
22.85
1Y Return
1.35%
1.35%
Buy Reco %
73.33
73.33
PE Ratio
59.39
59.39
1Y Return
14.22%
14.22%
Buy Reco %
70.83
70.83
PE Ratio
18.68
18.68
1Y Return
3.58%
3.58%
Buy Reco %
51.72
51.72
PE Ratio
52.37
52.37
1Y Return
20.17%
20.17%
Buy Reco %
81.25
81.25
Compare with Peers

NECLIFE Forecast

NECLIFE Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

NECLIFE

NECLIFE

Income

Balance Sheet

Cash Flow

NECLIFE Income Statement

NECLIFE Income Statement

Industry refers to the sub-sector this company belongs to.
Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -6.71%, vs industry avg of 10.1%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.94% to 0.4%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue1,666.371,882.292,788.912,370.701,547.081,680.151,566.851,698.661,674.971,674.97
Raw Materialssubtract1,145.851,417.322,268.131,862.831,052.821,207.321,200.841,242.451,699.531,699.53
Power & Fuel Costsubtract75.4491.85103.4792.7284.63101.41127.39129.52
Employee Costsubtract75.5474.6576.5478.1970.5971.9175.1481.71
Selling & Administrative Expensessubtract59.9852.2367.9967.0172.0466.8662.6461.39
Operating & Other expensessubtract62.484.062.5645.89179.4962.794.6617.46
Depreciation/Amortizationsubtract62.2564.3163.2660.7760.2556.9759.1260.7262.3962.39
Interest & Other Itemssubtract117.41115.20148.14125.83112.0478.8179.4987.1474.5874.58
Taxes & Other Itemssubtract12.0810.4111.225.68-11.509.03-18.2413.28-47.85-47.85
EPS2.472.332.121.42-3.271.12-1.080.22-5.07-5.07
DPS0.050.050.050.050.000.000.000.000.000.00
Payout ratio0.020.020.020.040.000.000.000.000.000.00

NECLIFE Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual report

PDF
 

NECLIFE Stock Peers

NECLIFE Past Performance & Peer Comparison

NECLIFE Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Nectar Lifesciences Ltd-3.250.35
Sun Pharmaceutical Industries Ltd36.655.530.96%
Cipla Ltd22.853.851.07%
Torrent Pharmaceuticals Ltd59.3914.950.18%

NECLIFE Stock Price Comparison

Compare NECLIFE with any stock or ETF
Compare NECLIFE with any stock or ETF
NECLIFE
Loading...

NECLIFE Holdings

NECLIFE Shareholdings

NECLIFE Promoter Holdings Trend

NECLIFE Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

High Pledged Promoter Holding
Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

NECLIFE Institutional Holdings Trend

NECLIFE Institutional Holdings Trend

Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.31%

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

NECLIFE Shareholding Pattern

NECLIFE Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding44.53%0.00%0.16%1.65%53.67%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

NECLIFE Shareholding History

NECLIFE Shareholding History

Dec '23MarJunSepDec '24Mar16.11%16.97%16.61%2.57%0.73%1.65%

NECLIFE Insider Trades & Bulk Stock Deals

NECLIFE Insider Trades & Bulk Stock Deals

Loading...

smallcases containing NECLIFE stock

smallcases containing NECLIFE stock

Looks like this stock is not in any smallcase yet.

NECLIFE Events

NECLIFE Events

NECLIFE Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

NECLIFE has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

NECLIFE Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

NECLIFE has not given any dividends in last 5 years

NECLIFE Upcoming Dividends

NECLIFE Upcoming Dividends

No upcoming dividends are available

NECLIFE Past Dividends

NECLIFE Past Dividends

Cash Dividend

Ex DateEx DateSep 11, 2020

Final
Final | Div/Share: ₹0.05

Dividend/Share

0.05

Ex DateEx Date

Sep 11, 2020

Cash Dividend

Ex DateEx DateSep 19, 2019

Final
Final | Div/Share: ₹0.05

Dividend/Share

0.05

Ex DateEx Date

Sep 19, 2019

Cash Dividend

Ex DateEx DateSep 19, 2018

Final
Final | Div/Share: ₹0.05

Dividend/Share

0.05

Ex DateEx Date

Sep 19, 2018

Cash Dividend

Ex DateEx DateSep 20, 2017

Final
Final | Div/Share: ₹0.05

Dividend/Share

0.05

Ex DateEx Date

Sep 20, 2017

Cash Dividend

Ex DateEx DateSep 22, 2016

Final
Final | Div/Share: ₹0.10

Dividend/Share

0.10

Ex DateEx Date

Sep 22, 2016

NECLIFE Stock News & Opinions

NECLIFE Stock News & Opinions

Spotlight
Nectar Lifescience Ltd leads losers in 'B' group

Lokesh Machines Ltd, Rhetan TMT Ltd, Vibhor Steel Tubes Ltd and Dreamfolks Services Ltd are among the other losers in the BSE's 'B' group today, 09 July 2025.Nectar Lifescience Ltd tumbled 9.93% to Rs 16.69 at 14:31 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 28.52 lakh shares were traded on the counter so far as against the average daily volumes of 2.2 lakh shares in the past one month.Lokesh Machines Ltd crashed 7.85% to Rs 218.85. The stock was the second biggest loser in 'B' group.On the BSE, 42757 shares were traded on the counter so far as against the average daily volumes of 12459 shares in the past one month.Rhetan TMT Ltd lost 7.75% to Rs 17.49. The stock was the third biggest loser in 'B' group.On the BSE, 21.83 lakh shares were traded on the counter so far as against the average daily volumes of 6.83 lakh shares in the past one month.Vibhor Steel Tubes Ltd slipped 5.35% to Rs 182.3. The stock was the fourth biggest loser in 'B' group.On the BSE, 6454 shares were traded on the counter so far as against the average daily volumes of 9926 shares in the past one month.Dreamfolks Services Ltd dropped 5.29% to Rs 167.55. The stock was the fifth biggest loser in 'B' group.On the BSE, 3.18 lakh shares were traded on the counter so far as against the average daily volumes of 1.15 lakh shares in the past one month.Powered by Capital Market - Live

16 hours agoCapital Market - Live
Corporate
Nectar Lifescience EGM scheduled

Nectar Lifescience announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 4 August 2025.Powered by Capital Market - Live

21 hours agoCapital Market - Live
Spotlight
Nectar Lifescience Ltd leads losers in 'B' group

Rajdarshan Industries Ltd, Sharda Motor Industries Ltd, PC Jeweller Ltd and PVP Ventures Ltd are among the other losers in the BSE's 'B' group today, 08 July 2025.Nectar Lifescience Ltd tumbled 19.99% to Rs 18.53 at 14:31 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 22 lakh shares were traded on the counter so far as against the average daily volumes of 1.27 lakh shares in the past one month.Rajdarshan Industries Ltd crashed 8.51% to Rs 52.6. The stock was the second biggest loser in 'B' group.On the BSE, 2204 shares were traded on the counter so far as against the average daily volumes of 1544 shares in the past one month.Sharda Motor Industries Ltd lost 7.27% to Rs 1132.25. The stock was the third biggest loser in 'B' group.On the BSE, 25991 shares were traded on the counter so far as against the average daily volumes of 8659 shares in the past one month.PC Jeweller Ltd plummeted 6.78% to Rs 17.45. The stock was the fourth biggest loser in 'B' group.On the BSE, 356.88 lakh shares were traded on the counter so far as against the average daily volumes of 91.41 lakh shares in the past one month.PVP Ventures Ltd fell 6.06% to Rs 20.91. The stock was the fifth biggest loser in 'B' group.On the BSE, 1.21 lakh shares were traded on the counter so far as against the average daily volumes of 26062 shares in the past one month.Powered by Capital Market - Live

1 day agoCapital Market - Live
Spotlight
Nectar Life slumps on selling core pharma business to Ceph Lifesciences for Rs 1,270 Cr

The deal, executed on a slump sale basis, includes the manufacture, distribution, and marketing of APIs (active pharmaceutical ingredients) and formulations. As part of the broader restructuring, Nectar has also signed an asset purchase agreement to divest its menthol business assets to Ceph Lifesciences for an additional Rs 20 crore. The transaction, expected to be completed by 20 September 2025, is subject to shareholder approval at an extraordinary general meeting scheduled for August 4. According to the company, this sale marks a significant pivot toward becoming a more focused and innovation-driven enterprise. Proceeds from the deal will be used to repay existing debt, invest in emerging opportunities, potentially reward shareholders and fund future growth initiatives. The buyer, Ceph Lifesciences, is a non-promoter entity with no impact on Nectar's existing shareholding pattern post-transaction. Sanjiv Goyal, promoter and chairman of Nectar Lifesciences, commented: This transaction marks a significant milestone in Nectar Lifesciences' evolution. By divesting mature segments of our business, we are laying the foundation for a focused and agile organization geared towards innovation and long-term value creation. We thank our stakeholders for their continued trust and support as we embark on this next chapter. Nectar Lifesciences is a pharmaceutical company focused on research-driven innovation, manufacturing, and global distribution. The company will announce Q4 results on 7 July 2025. On a consolidated basis, net profit of Nectar Lifescience soared 399.36% to Rs 7.84 crore while net sales rose 0.48% to Rs 454.33 crore in Q3 December 2024 over Q3 December 2023. Powered by Capital Market - Live

1 day agoCapital Market - Live
Corporate
Nectar Lifescience to discuss results

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 7 July 2025.Powered by Capital Market - Live

5 days agoCapital Market - Live
Corporate
Nectar Lifescience schedules board meeting

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Nectar Lifesciences slumps after Mohali unit gets seven observations from EU authorities

In a regulatory filing made after market hours yesterday, the company stated that its API manufacturing facility in Saidpura, Mohali, Punjab, underwent a joint inspection by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and the Spanish Agency of Medicines and Medical Devices (AEMPS) to assess compliance with EuGMP standards. Following the inspection, seven observations including four critical, were noted. Nectar Lifesciences said that it is in the process of preparing a corrective action and preventive action (CAPA) report to address the observations. The company emphasized its commitment to quality and compliance with cGMP standards. The European regulator will conduct a re-inspection of the facility to verify the compliance and CAPA submitted which may lead to EuGMP approval. Nectar Lifesciences is a research-based pharmaceutical company, primarily engaged in manufacturing APIs and formulation. The company has four manufacturing facilities across Punjab and Himachal Pradesh. The company is into manufacturing Cephalosporin (oral and sterile) at its two units in Derabassi and Punjab. The company's consolidated net profit surged to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in Q3 FY25 as compared with Q3 FY24. Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Nectar Lifescience consolidated net profit rises 399.36% in the December 2024 quarter

Net profit of Nectar Lifescience rose 399.36% to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in the quarter ended December 2024 as against Rs 452.16 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales454.33452.16 0 OPM %9.849.33 - PBDT28.1617.83 58 PBT12.552.46 410 NP7.841.57 399 Powered by Capital Market - Live

5 months agoCapital Market - Live
Corporate
Nectar Lifescience announces board meeting date

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 31 January 2025.Powered by Capital Market - Live

5 months agoCapital Market - Live
Earnings
Nectar Lifescience consolidated net profit rises 449.02% in the September 2024 quarter

Net profit of Nectar Lifescience rose 449.02% to Rs 5.60 crore in the quarter ended September 2024 as against Rs 1.02 crore during the previous quarter ended September 2023. Sales rose 7.52% to Rs 427.88 crore in the quarter ended September 2024 as against Rs 397.96 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales427.88397.96 8 OPM %10.136.75 - PBDT24.2116.95 43 PBT8.671.64 429 NP5.601.02 449 Powered by Capital Market - Live

7 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Nectar Lifesciences Ltd (NECLIFE) today?

    The share price of NECLIFE as on 9th July 2025 is ₹16.47. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Nectar Lifesciences Ltd (NECLIFE) share?

    The past returns of Nectar Lifesciences Ltd (NECLIFE) share are
    • Past 1 week: -20.26%
    • Past 1 month: -24.18%
    • Past 3 months: -27.35%
    • Past 6 months: -56.58%
    • Past 1 year: -46.91%
    • Past 3 years: -30.65%
    • Past 5 years: -25.14%

  3. What are the peers or stocks similar to Nectar Lifesciences Ltd (NECLIFE)?
  4. What is the market cap of Nectar Lifesciences Ltd (NECLIFE) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Nectar Lifesciences Ltd (NECLIFE) is ₹369.36 Cr as of 9th July 2025.

  5. What is the 52 week high and low of Nectar Lifesciences Ltd (NECLIFE) share?

    The 52-week high of Nectar Lifesciences Ltd (NECLIFE) is ₹56.50 and the 52-week low is ₹15.51.

  6. What is the PE and PB ratio of Nectar Lifesciences Ltd (NECLIFE) stock?

    The P/E (price-to-earnings) ratio of Nectar Lifesciences Ltd (NECLIFE) is -3.25. The P/B (price-to-book) ratio is 0.35.

  7. Which sector does Nectar Lifesciences Ltd (NECLIFE) belong to?

    Nectar Lifesciences Ltd (NECLIFE) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. How to buy Nectar Lifesciences Ltd (NECLIFE) shares?

    You can directly buy Nectar Lifesciences Ltd (NECLIFE) shares on Tickertape. Simply sign up, connect your demat account and place your order.